Leadership Changes Boost Confidence in uniQure's Huntington's Disease Gene Therapy Progress

### Leadership Change Fuels Optimism for uniQure N.V.’s Huntington's Disease Gene Therapy

Recent leadership shifts at uniQure N.V. have engendered renewed optimism regarding the company's gene therapy for Huntington's disease, known as AMT-130. Following the departure of a pivotal executive, investors perceive this change as a potential facilitator in navigating the intricate regulatory landscape associated with AMT-130. The biopharmaceutical sector is characterized by its rigorous regulatory requirements, and the perception that new leadership might streamline these processes is crucial for the timely development and introduction of groundbreaking therapies like AMT-130.

The urgency for effective treatments for Huntington's disease is palpable, with a substantial unmet medical need reflected in the increasing focus on addressing this degenerative disorder. The positive response from investors, evidenced by a 26.07% surge in stock price, underscores a collective belief that the new strategic direction may enhance the company’s capacity to overcome regulatory hurdles more swiftly. A successful navigation through these challenges is critical, as the regulatory approval not only legitimizes AMT-130 but also positions uniQure as a leader in the development of innovative healthcare solutions that cater to a demographic significantly affected by this condition.

As uniQure progresses with AMT-130, the company stands on the cusp of reshaping its identity within the biopharmaceutical industry. This leadership transition not only alters internal dynamics but also rejuvenates shareholder confidence, suggesting that corporate governance changes can play a pivotal role in biopharma success. With the anticipation of a smoother regulatory journey, the firm is poised to potentially accelerate the timeline for bringing AMT-130 to those in dire need, reinforcing its commitment to pioneering next-generation therapies.

In related news, The Gross Law Firm has issued a notice to shareholders regarding potential legal actions linked to allegations of misleading statements made by uniQure between September 24, 2025, and October 31, 2025. These allegations pertain to undisclosed information about the FDA approval status of uniQure’s Pivotal Study, including a demand for additional studies that could defer the Biologics License Application submission. Shareholders from this period are invited to register for possible lead plaintiff status in the legal proceedings, setting a registration deadline of April 13, 2026.

The law firm, known for its focus on class action lawsuits, is committed to protecting investors' rights and holding companies accountable for transparency in their operations. Interested shareholders are encouraged to reach out for more information.